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Abstract
Mental illness and opioid dependence are common comorbidities that may affect individuals’ clinical outcomes on Opioid Substitution Therapy (OST) treatment. 
Though many associations have been described, the long-term impacts of common comorbid mental illnesses on OST treatment progress remain poorly understood. 
This is particularly relevant when there is a renewed drive to improve progress towards recovery in OST patients.
Aims: Using the scaled General Health Questionnaire (GHQ28) and other validated instruments, this prospective cohort study aimed to describe the prevalence 
of psychiatric caseness in a large representative cohort of methadone-prescribed substance misusers and to explore the relationships between these psychiatric 
comorbidities, clinical process and long-term outcomes over 7 years.
Design and Methods: A baseline cohort of 623 methadone OST patients was assessed using a range of validated instruments. Seven year follow up data were collected 
using casenote review and health informatics procedures.
Results: GHQ-derived psychiatric caseness was identified in 58.4% at baseline but showed no significant associations with clinical process or 7-year outcomes. 
Post-Traumatic Stress Disorder was more prevalent than previously described while ADHD was less prevalent. Significant associations were demonstrated between 
baseline psychiatric comorbidities and substance misuse risk behaviours, clinical processes and associated 7-year outcomes.
Conclusions and discussion: Psychiatric comorbidity is common though studies show considerable variation in prevalence. Common psychiatric comorbidities 
impact upon long term substance use outcomes in OST patients. The relationships, however, are complex. These relationships must be better understood to improve 
OST outcomes and opportunities for progress towards recovery.
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Introduction
Opioid dependency is the dominant illicit drug problem worldwide, 
with an estimated annual prevalence in the general population of 0.3-
0.5% [1]. It follows a chronic, relapsing clinical course and abstinence, 
if achieved, must be sustained for many years to promote continued 
recovery and reduce likelihood of relapse [2]. Traditionally, therapeutic 
intervention aims to reduce drug-related harms, typically using drug 
substitution strategies.
More recently, services have been encouraged to also deliver 
‘recovery’ [3]. Opioid Substitution Therapy (OST) appears effective in 
terms of delivering harm-reduction outcomes [4]. The evidence base 
demonstrating the influence of OST on progress towards recovery, 
however, remains limited [5]. High levels of psychiatric comorbidity 
have been consistently identified in surveys of substance misusers [6]. 
Despite this, OST services often fail to diagnose or treat psychiatric 
comorbidities, potentially resulting in poorer short-term treatment 
outcomes [7]. Indeed, it has been proposed that screening for psychiatric 
symptoms, or “caseness” should be promoted in addiction services 
[8]. The study of the impact of psychiatric comorbidity on substance 
misuse outcomes is further complicated by the heterogeneity and 
relapsing-remitting course of both domains of disorder [6]. A recent 
systematic review considering the treatment of psychiatric comorbidity 
in substance users acknowledged the general paucity of the evidence 
base and the subsequent difficulty in evidencing the most effective 
treatments [9]. Some studies have considered the potential impact 
of comorbidity on the effectiveness of methadone OST itself. Many 
have been unable to demonstrate any significant effect of psychiatric 
comorbidity on treatment retention or substance misuse outcomes. In 
other studies, various psychiatric diagnoses – anxiety, depression, Post-
Traumatic Stress Disorder (PTSD) and Attention Deficit Hyperactivity 
Disorder (ADHD) - have all been implicated in exerting negative effects 
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on short term clinical outcomes, although causal relationships have 
not been established [10-19]. It has also been hypothesised that current 
psychiatric symptoms – rather than any formal syndromal psychiatric 
diagnosis - may be the key factor influencing treatment effectiveness in 
opioid-dependency [7,9].
Thus, despite the widespread acknowledgement that psychiatric 
comorbidity is common in opioid dependency, the effect on OST 
outcomes is poorly understood. As expectations for OST increase, 
there is a need to better understand the potential impact of comorbid 
mental illness. Therefore, the present study aimed:
1. To assess the prevalence of psychiatric caseness in a large 
representative cohort of OST patients; and
2. To consider the relationships between baseline indicators of 
psychiatric comorbidity and outcomes over 7 years.
Methods
Detailed clinical data were collected from methadone OST patients 
(n=623), resident in a single Scottish region, in 2005. Four years later, 
follow-up data were collected by structured casenote review. These 
data were then linked, using unique identifiers, with validated health 
informatics datasets describing clinical contacts and outcomes from 
2005-12. The resulting database contained detailed information on the 
baseline cohort over this 7-year period. Standard operating procedures 
at HIC Services, University of Dundee, were followed to ensure 
anonymisation of the dataset. HIC Services is a University of Dundee 
research support unit within the Tayside Medical Science Centre 
(TASC). It operates a secure “safe haven” environment with robust 
data governance for the provisioning of clinical data to academics 
for research (http://medicine.dundee.ac.uk/hic). Ethics Committee 
guidance was sought and full Ethics Committee approval was not 
required. NHS Caldicott Guardian agreement was obtained to cover all 
aspects of data handling and sharing. (Figure 1).
Identification of Baseline Cohort (2005)
In January 2005, all patients in receipt of methadone OST in 
Tayside region, Scotland were identified from NHS databases (n=817). 
Only methadone was used as OST in Tayside at this time. Only Tayside 
residents in a defined OST programme were included. Patients were 
provided with written information prior to review appointments. 
Interviews were conducted by experienced, trained, substance misuse 
nurses in NHS facilities. Every effort was taken to include all regional 
OST patients in the review. Non-attenders were offered further 
appointments at their convenience. Further non-attendance resulted 
in written communication through their community pharmacy to 
encourage participation.
 
Figure 1. Study data collection  
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Baseline data collected and instruments used
Substance use status was assessed using the Maudsley Addiction 
Profile (MAP) [20],
Injection Risk Questionnaire (IRQ) [21] and Treatment Perception 
Questionnaire (TPQ) [22].
Comorbid mental health caseness was determined using the 
General Health Questionnaire – Scaled version (GHQ - 28). The GHQ 
is a well-established self-administration screening instrument designed 
to detect probable psychiatric disorder, previously proposed as a 
screening tool in substance users [8]. The GHQ-28 is more convenient 
for patients and has been used in a wide range of clinical settings [23].
Screens for specific psychiatric conditions were also undertaken. 
A range of validated instruments, mainly self-completion 
questionnaires, were chosen to minimise administrative burden and 
to avoid disruption to clinical services. The Social Phobia Diagnostic 
Questionnaire (SPDQ) was used to screen for Social Phobia. This brief 
self-report questionnaire has been shown to be reliable and valid in a 
range of populations. It addresses the DSM IV diagnostic criteria for 
social phobia [24]. The Impact of Events Scale (IES) was used to screen 
for Post-Traumatic Stress Disorder (PTSD). The IES is a screen for 
traumatic experiences and can detect likely PTSD. It is recommended 
for use in a clinical setting and has been used as a screening tool in a 
range of general populations [25].
Attention Deficit Hyperactivity Disorder (ADHD) was screened 
using the Current Symptoms Scale (CSS). The CSS has been found to 
be a useful screening tool in a range of populations and was included as 
it was one of only a few briefs, validated self-completion questionnaires 
available [26].
A bespoke database was built using SPSS 16 (SPSS 2003). Data 
were input by experienced HIC Services data-entry staff with rigorous 
quality assurance through a comparison of 10% of database entries 
against the hard copy information.
Follow up data
In 2009, a follow up review of the 2005 cohort was undertaken. 
A bespoke proforma captured information from clinical records. All 
data (2005 baseline and 2009 casenote reviews) were lodged in HIC 
Services’ “safe haven”. In 2012, these data were linked with datasets 
that supplied information describing demographics (available through 
the NHS Scotland Community Health Index – CHI), use of NHS 
services (available through the Scottish Morbidity Records - SMR) and 
outcomes (e.g. deaths available from the Registrar General records). 
Once linked, HIC Services supplied each subject with a new unique 
identifier (or “ProCHI”) making a fully anonymised dataset available 
for analysis through a secure IT portal. Table1. shows the data used in 
the analyses. All data were analysed using SPSS v18 (IBM 2010). (Table 1)
Statistical analysis
Descriptive analyses were used to describe the baseline sample, 
reported as number (percentage) for categorical variables and mean 
(SD) for continuous variables. Univariate associations between baseline 
and follow up data were assessed. Categorical data were compared 
using the chi-squared test. Testing of continuous data was determined 
by normality of distribution. Normally distributed data were subject 
to parametric tests with Bonferroni corrections applied to reduce the 
likelihood of Type 1 error. Effect sizes were calculated.
Results
Representativeness of samples
At baseline, 817 Tayside patients were in receipt of methadone OST, 
of which 623 (76.2%) were assessed. Means and standard deviations 
of selected descriptive variables – age, gender and methadone dose 
- were collected in order to assess representativeness of this baseline 
sample compared with the known total OST population. In the 
assessed participants, males were over-represented (Chi-squared test; 
χ2(1) =7.064; p=0.008), mean age was older (t-test; t=3.4; p=0.001), 
and methadone dose lower (t-test; t=2.3; df=752; p=0.022) than in 
the total treatment population. At 4-year follow-up, clinical records 
were accessed for 467 subjects (75% of those assessed at baseline). 
Comparisons with those not reviewed were made regarding variables 
including age, gender, residence, educational attainment, employment 
status and living circumstances. No significant differences were 
found, confirming that the casenote follow-up sample was generally 
representative of the baseline assessment sample. For informatics 
follow-up data, all data-linked records were available for all clinical 
episodes for all individuals from 2005-2012.
Independent variable Dependent variable (4 yr-casenote reviews) 
Psychiatric caseness (GHQ28) Process measures 
GHQ 28 caseness Retained on treatment - 4 years 
GHQ 28 Total score If discharged – positive or negative 
Anxiety disorders  Methadone dose 
Social phobia caseness (as SPDQ) Diazepam dose 
PTSD caseness (IES cut off 26) Regular drug screen done 
PTSD severity (IES total score) Outcome measures 
ADHD Employment status 
ADHD Symptoms (CSS) Family stability (proxy - living with children) 
ADHD type (CSS) Any illicit drug use reported 
ADHD impairment (CSS) Heroin use reported 
 
Heroin use (days) 
Heroin use (route) 
Diazepam use reported 
Diazepam days 
Illicit methadone use reported 
Illicit methadone days 
Illicit painkiller (other opiate) use 
Illicit painkiller days 
Test positive opiates 
Test positive benzodiazepines 
Acute hospital admissions reported 
Psychiatric hospital admissions reported 
Incarceration reported 
Dependent Variables (7yr-HIC linked 
datasets) 
Process measures 
SMR00 (out-patient) sessions (number) 
Outcome measures 
SAS (Ambulance) attendances 
Naloxone administrations 
A&E attendances 
SMR01 admissions (acute) - All 
SMR01 duration (acute nights) - All 
SMR04 admissions (psychiatric) 
SMR04 (psych) emergency/routine 
SMR04 admissions - total days 
SMR04 admissions - longest stay 
GROS dead/alive 
Table 1. Variables used in longitudinal analyses 
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Demographics and personal circumstances at baseline
Four hundred and twenty four of the cohort were male (68.4%). 
Three hundred and eighty two (61.6%) lived in an inner city area and 
483 (77.9%) within the 2 most deprived quintiles as assessed using 
the Scottish Index of Multiple Deprivation (SIMD) [27]. The majority 
(443 participants - 75.7%) were parents with at least one child. Over 
half (370 participants - 55.5%) reported that they were living with a 
partner though the mean contact frequency was 15/30 days (SD 14.4). 
Educational attainment was poor with 312 (52.6%) having gained 
no qualifications and 61% of those with any qualifications having 
achieved elementary qualifications only. Only 63 (13%) were in paid 
employment, working a mean of only 2 days per month.
Substance misuse treatment at baseline
Five hundred and eighty-eight participants (97%) were found to 
be in receipt of a methadone prescription as, having been identified at 
the inception date, some had completed detoxification, or ceased to be 
prescribed methadone for some other reason. Mean dose was 49.5mg 
(SD 25.3), range 0-170mg and mode 50mg. One hundred and seventy-
eight (29%) were also prescribed diazepam. Mean dose was 6.8mg (SD 
13.6, range 0-85mg; mode 20mg). OST was being delivered in three 
settings: NHS specialist service – 298 subjects (47.4%); Criminal Justice 
services – 93 subjects (14.8%); General Practice Shared-Care – 156 
subjects (24.8%).
Drug use, injecting risks, general health and support (MAP)
Two hundred and eighty nine (54%) of participants’ urine drug 
screens tested positive for heroin at their baseline review appointment 
while 314 (58.9%) tested positive for diazepam. Only 178 (29%) were 
prescribed diazepam. Only 87(16.2%) reported any injecting. Of those 
who injected, the mean number of injecting days within the last 30 was 
1.9 (range 0-30 days; SD 6.1). Mean frequency of daily injecting was 0.3 
injections/day (range 0-5 injections; SD 0.7). Four hundred and fifty 
(83.8%) stated they never shared injecting equipment, while of the 82 
who reported any sharing, 4 (4.9%) stated they shared “frequently”. 
Regarding general health, 580 participants (93.5%) were registered with 
a GP. Two hundred and ninety three (51.7%) reported having physical 
health problems for which 177 (60%) were receiving treatment. Mean 
MAP physical health score was 14.2 (SD 7.98) suggesting that physical 
health problems were mild/moderate. Two hundred and sixty five 
(49.7%) reported mental health problems for which 184 (69%) were 
being treated. Mean MAP psychological health score was 15.73 (SD 
9.22) suggesting that mental health problems were mild/moderate. 
Only 152 (30%) were receiving additional support from non-NHS 
agencies. 
Mental health Co-morbidity
The results of the mental health screens are shown in Table 2.
Three hundred participants (58.4% of 514 screened) scored above 
the recommended threshold for caseness on the GHQ-28 [23]. Two 
hundred and fifteen (40% of 539 screened) met criteria for a diagnosis 
of Social Phobia [24]. Using the Impact of Events Scale, 280 subjects 
(48% of the 601 screened) had a high likelihood of having a form of Post 
-Traumatic Stress Disorder [25]. Only 368 subjects were specifically 
screened for ADHD at baseline. Of these, 59 (16%) were shown to have 
any symptoms of ADHD with the majority falling into the “inattentive” 
sub-group [26].
Associations – psychiatric comorbidity and 4-7-year outcomes
The associations between baseline screening results and outcomes 
are shown in Table 3.
 N % Mean median Mode Min-max SD 
General Health Questionnaire (GHQ28) 
Total score (514)   28.11 26 21 1-78 13.609 
Likert threshold for caseness: 23/24 (514) 
Yes - caseness 300 58.4      
No - caseness 214 41.6      
Social Phobia Diagnostic Questionnaire (SPDQ) 
Total score (539)   6.88 0 0 0-27 8.587 
Likert threshold for social phobia: 21/22 
Yes - caseness 215 40%      
No - caseness 323 60%      
Impact of Events Scale (IES) 
Total score (601)   23.90 19 0 0-75 24.981 
Likert threshold for caseness: 26 
Yes - caseness 280 48%      
No - caseness 299 52%      
Avoidance score    14.04 14.00 0 0-65 13.390 
Intrusion score    13.06 13.00 0 0-35 12.383 
Current Symptoms Scale (CSS) 
Presence/type of ADHD N % 
Any ADHD? (n=368) 
No ADHD 309   
ADHD present 59 16% 
Type of ADHD (59) 
Inattentive 31 52.5% 
Hyperactive/impulsive 8 13.6% 
Combined 20 33.9% 
Table 2. Baseline screens for mental health comorbidity 
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Four year follow up – casenote reviews
Few associations were found between the baseline comorbidity 
screens and 4-year outcomes. GHQ-28 caseness showed no significant 
associations with these measures. A higher GHQ-28 total score was 
associated with more illicit drug use (diazepam use; illicit methadone 
days used). No associations were found between baseline Social phobia 
and 4-year outcomes. PTSD caseness was associated with a higher 
prescribed methadone dose and less family stability while severity of 
PTSD symptoms (IES total score) was also associated with a higher 
prescribed methadone dose. There were no significant associations 
found between baseline ADHD and 4-year outcomes.
Seven-year follow-up – HIC linked datasets
At 7-year review, GHQ-28 caseness status showed no significant 
associations with any outcomes. Higher GHQ-28 total scores, however, 
were associated with more psychiatric admissions. No associations 
were found between baseline Social Phobia and 7-year outcomes. PTSD 
caseness was associated with an increased likelihood of emergency 
ambulance call-outs during the follow up period. Presence of any type 
of ADHD at baseline was associated with an increased likelihood of 
administration of naloxone to treat overdose during an emergency 
ambulance call-out. Those found to have the hyperactive type of 
ADHD were likely to be offered more outpatient clinic appointments 
over the seven year follow up period than other subjects.
Discussion
Strengths and limitations
We conducted a detailed assessment of a large representative 
sample of an OST treatment population within a defined geographical 
area. The demographic characteristics of this sample show them to be 
very similar to those described in previous large UK cohort studies 
[28,29]. The subjects were screened for the presence of comorbid 
psychiatric conditions using validated instruments. We have collected 
follow up data on clinical processes, service utilisation and outcomes 
on over 600 subjects over 7 years, allowing assessment of the long term 
impact of psychiatric comorbidity on OST effectiveness.
4 year follow up results (case note review) 
Independent variable Dependent variable Statistics 
GHQ caseness  All NSD 
GHQ total score 
Illicit diazepam use 
LDA X2(1) =6.686; p=0.010 
Higher score=more likely use 
 Cohen’s d = 0.367 R=0.180  
Small effect size 
Illicit methadone days 
LRA X2(3) = 13.755; p=0.003 Higher score=more days 
use/30 
Partial ɳ2 = 0.118  
Medium effect size 
SPDQ caseness All NSD 
PTSD caseness 
601 total scores of whom 271 scored zero.  280 show PTSD 
“caseness” based on cut off of 26 on scale. 321 no PTSD.  
Family stability 
Chi square X2(2) =6.648; 
p=0.036 
PTSD caseness=less stability 
Cramer’s V=0.122 p=0.036 
Relevant effect 
Methadone dose 
KWH X2(1) =5.009; p=0.025 
PTSD caseness =higher dose 
Partial ɳ 2 = 0.001  
Small effect size 
PTSD severity score  
Of cases, severity scale shows 
175 “severe” and 105 
“moderate” 
Methadone dose 
QRA t (1) =-2.674; p=0.008  
Higher Score=higher dose 
Partial ɳ2 =0.003  
Small effect size 
ADHD symptoms present/type All NSD 
7 year follow up results (data-linkage) 
GHQ caseness  All NSD 
GHQ total score Psychiatric admissions (SMR04) 
LRA t (1) =2.643; p=0.011 
Higher score = more IP days 
Partial ɳ2 = 0.995  
Large effect size 
SPDQ caseness All NSD 
PTSD caseness Ambulance callouts (OD) 
MWU=349.500; p=0.050 
PTSD=more call outs 
Partial ɳ2 = 0.021 
 Small effect size 
PTSD severity score All NSD 
ADHD symptoms Naloxone administrations 
MWU=20.500; p=0.031 
ADHD = more naloxone events 
Partial ɳ2 = 0.235  
Large effect size 
ADHD type Out-patient attendance 
KWH(2)=7.009; p=0.030 Hyperactive=more attendances 
Partial ɳ2 = 0.070  
Medium effect size 
Table 3. Associations baseline comorbidity screens on process, service utilization and outcomes 
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Missing data
This study also has a number of shortcomings, however. Subjects 
were already in treatment at baseline – and information about previous 
treatment was unavailable. This study has focused on the relationship 
between outcomes and presence or absence of psychiatric comorbidity. 
Other patient characteristics– relating to previous drug history, 
presence of physical comorbidity (e.g. chronic pain) or social factors 
- may be important influences. It would also have been useful to have 
access to more objective measures of harm reduction effectiveness 
– such as blood-borne virus sero-conversion. These data were not 
available at the time of this study.
Representativeness of samples
Statistical evaluation, at all stages of data collection, determined 
whether the samples were representative. Though the baseline sample 
represented 76% of all methadone OST patients in the region, the 
subjects assessed did show significant differences when compared 
to the total population. This may reflect the review process – which 
was part of a clinical service review, was time limited and invited 
individuals to attend. There may be both positive and negative reasons 
that this sub-group –younger females taking higher OST doses - were 
less likely to present for assessment. This is a weakness of the study 
– despite the large sample. The 4 year follow up sample represented 
75% of the baseline cohort. No significant differences were found when 
comparing the follow-up sample with the population of interest.
Stability of sample at baseline
The baseline urine drug screens found over half (54%) to be positive 
for illicit opiate use while 314 subjects (58.9%) tested positive for use 
of benzodiazepines. Only 178 (29%) were prescribed benzodiazepines, 
suggesting considerable illicit benzodiazepine use in this sample. These 
treatment services traditionally delivered a harm-reduction orientated 
model of care. In such services it is not unusual for patients not to be 
completely abstinent and one-off testing is seen as a poor indicator of 
stability [30]. Data which would allow objective assessment of frequency 
of use - such as repeated urine drug screens - were unavailable. 
However, though illicit use was prevalent, reported risk-taking was 
low. Only a small proportion of those assessed - 87 subjects (16%) - 
were injecting at baseline with very few sharing injecting equipment.
Instruments
The main instruments were chosen because of their relevance from 
previous published research. The MAP has been a standard assessment 
tool for substance use studies [28-30]. The GHQ-28 was introduced 
to screen for psychiatric caseness. This instrument has been validated 
in a number of clinical settings and has been proposed as a useful 
screener for psychiatric comorbidity in substance users [8,23]. Some of 
the additional instruments used to screen for psychiatric comorbidity 
at baseline, however, may limit this study. They were chosen as the 
baseline data collection process was carried out in a clinical service 
where specific instruments were already being used and time limitations 
were in place, making use of self-completion questionnaires, with no 
added cost to services, preferable.
Prevalence of psychiatric comorbidity
We found that 58.4% of those screened met the GHQ-28 criteria 
for psychiatric caseness, confirming a high prevalence of psychiatric 
symptoms in this treatment population. It has been suggested that 
anxiety disorders are common in substance users and may be up to 
twice as common in this population when compared to the general 
public [31]. Forty percent of those who were assessed met the threshold 
criterion for Social Phobia caseness while 48% met the criteria for PTSD 
caseness. This is a much higher rate than of the 28% previously reported 
in opioid dependent subjects [18]. Findings were very different for 
ADHD, however, with only 16% of those screened showing symptoms 
suggestive of ADHD using the CSS. This figure is low in comparison to 
previously published work that has suggested prevalence levels as high 
as 58% [19]. We are unable to determine whether these findings reflect 
varying levels of comorbidity over time in this population or the choice 
of screening tool.
Impact on outcomes
Although a range of medical treatments are available to manage 
opioid dependence, methadone OST is the prominent treatment of 
choice in many countries [4]. Previous research has given conflicting 
results regarding the potential impact of various psychiatric 
comorbidities on OST effectiveness, with some studies unable to 
demonstrate any effect on retention or clinical outcomes while other 
studies have proposed negative effects on outcome associated with 
the presence of anxiety, depression, PTSD or ADHD [4,10-19,32]. 
Meanwhile, some researchers have argued that undiagnosed psychiatric 
comorbidity is a risk factor for poorer retention in treatment [33]. 
These conflicting findings may reflect the methods used in these studies 
– which have focused on specific psychiatric diagnoses and have 
generally reported only short term OST outcomes. Some authorities 
have proposed that current symptoms or levels of distress may have 
more effect on substance use outcomes than formal DSM IV diagnoses. 
The limitations of the evidence base on comorbidity to date are well 
described [7-9]. As the expectations OST increase, it is important that 
these relationships are better understood.
In this study we have evaluated multiple measures of treatment 
process and clinical outcomes in a large representative sample from a 
regional NHS treatment service over 7 years and considered whether the 
presence/absence of psychiatric comorbidity at baseline is associated 
with poorer outcomes. Like the evidence base to date, our findings are 
inconsistent. We found that meeting the psychiatric caseness threshold 
on the GHQ-28 did not correlate with either poorer engagement with 
the treatment process, nor clinical outcomes. Anxiety disorders are 
common in substance misusers [31]. We screened for the presence of 
Social Phobia and found a prevalence of 40%. We found this, however, 
to have no associations with clinical processes or outcomes over the 
7 year follow up period. Previous research has suggested that PTSD 
is associated with the development of more severe drug dependency/
addictive behaviours, is associated with more disability and poorer 
work prospects and is harder to treat successfully with OST (requiring 
more intensive psychosocial inputs and higher methadone doses to 
achieve positive outcomes) [18,32]. We screened for PTSD and found 
48% of those screened to have PTSD caseness – a higher level than 
previously reported. We demonstrated that, at 4 year follow up, both 
PTSD symptoms (total score) and caseness were associated with higher 
doses of prescribed methadone – perhaps reinforcing these previous 
studies’ findings. Clinical outcomes assessed in this study were not, 
however, significantly associated with PTSD status at baseline. PTSD 
cases were less likely to show evidence of family stability at 4 years. 
Over 7 years PTSD cases were more likely to have required emergency 
ambulance callouts – perhaps suggesting higher levels of risk-taking. 
ADHD has previously been reported as having a high prevalence and the 
presence of ADHD has been shown to be associated with much poorer 
short term outcomes than those with no ADHD diagnosis [19]. In the 
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current study, only 16% were found to have symptoms suggestive of 
ADHD. We did not find ADHD was associated with substance misuse 
outcomes in general but did find that those with any ADHD symptoms 
were more likely to have required naloxone treatment administration 
than those without over the 7 year follow up period, suggesting this 
group may be more likely to be involved in risky behaviour than their 
peers. In terms of the treatment process, perhaps reflecting assessment 
of risk, those with symptoms suggestive of the hyperactive subtype 
ADHD received significantly more out-patient appointments during 
the 7 year follow up period than others.
There is a drive to improve the outcomes achieved in OST. 
Psychiatric comorbidities are common and may be an important factor 
which, if not addressed, has the potential to reduce treatment effectiveness 
– both in terms of poorer harm reduction outcomes and recovery.
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